BACKGROUND AND AIMS: There are no available effective therapies for fatigue associated with chronic hepatitis C (CHC). The serotonin antagonist ondansetron has been shown to be effective in the chronic fatigue syndrome. In this randomised, placebo controlled, double blind trial, we investigated the effect of orally administered ondansetron on fatigue in CHC. METHODS:Thirty six patients with CHC were included if fatigue was their predominant symptom and they scored more than 4 on a visual analogue scale (0-10). During the study, fatigue and depression were measured on days 0, 15, 30, and 60 using a validated self report questionnaire (fatigue impact scale and Beck depression inventory). Patients were randomised to receive ondansetron tablets 4 mg twice daily or placebo for one month followed by an additional four weeks of observation. RESULTS:Fatigue score was 85.4 (28.2) and 98.2 (26.9) in the ondansetron and placebo groups, respectively (NS). Ondansetron significantly reduced the fatigue score with more than 30% improvement on day 15 (57.1 (38.9); p<0.01), day 30 (54.5 (37.6); p<0.01), and day 60 (60.8 (37.3); p<0.01) whereas placebo did not. Overall, the reduction in fatigue was significantly higher with ondansetron compared with placebo (ANOVA for repeated measurements) for the whole follow up period (p = 0.03) or for the treatment period only (p = 0.04). Ondansetron also significantly reduced depression scores. CONCLUSIONS: The 5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect on fatigue in CHC. These observations support the concept that fatigue involves serotoninergic pathways and may encourage further evaluations of the efficacy of ondansetron on fatigue in chronic liver diseases.
RCT Entities:
BACKGROUND AND AIMS: There are no available effective therapies for fatigue associated with chronic hepatitis C (CHC). The serotonin antagonist ondansetron has been shown to be effective in the chronic fatigue syndrome. In this randomised, placebo controlled, double blind trial, we investigated the effect of orally administered ondansetron on fatigue in CHC. METHODS: Thirty six patients with CHC were included if fatigue was their predominant symptom and they scored more than 4 on a visual analogue scale (0-10). During the study, fatigue and depression were measured on days 0, 15, 30, and 60 using a validated self report questionnaire (fatigue impact scale and Beck depression inventory). Patients were randomised to receive ondansetron tablets 4 mg twice daily or placebo for one month followed by an additional four weeks of observation. RESULTS:Fatigue score was 85.4 (28.2) and 98.2 (26.9) in the ondansetron and placebo groups, respectively (NS). Ondansetron significantly reduced the fatigue score with more than 30% improvement on day 15 (57.1 (38.9); p<0.01), day 30 (54.5 (37.6); p<0.01), and day 60 (60.8 (37.3); p<0.01) whereas placebo did not. Overall, the reduction in fatigue was significantly higher with ondansetron compared with placebo (ANOVA for repeated measurements) for the whole follow up period (p = 0.03) or for the treatment period only (p = 0.04). Ondansetron also significantly reduced depression scores. CONCLUSIONS: The 5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect on fatigue in CHC. These observations support the concept that fatigue involves serotoninergic pathways and may encourage further evaluations of the efficacy of ondansetron on fatigue in chronic liver diseases.
Authors: T Lempérière; J P Lépine; F Rouillon; P Hardy; J Ades; J P Luaute; I Ferrand Journal: Ann Med Psychol (Paris) Date: 1984-11 Impact factor: 0.380
Authors: Jennifer Goldblatt; Philip J S Taylor; Toby Lipman; Martin I Prince; Anna Baragiotta; Margaret F Bassendine; Oliver F W James; David E J Jones Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: G Calapai; F Corica; A Corsonello; L Sautebin; M Di Rosa; G M Campo; M Buemi; V N Mauro; A P Caputi Journal: J Clin Invest Date: 1999-10 Impact factor: 14.808
Authors: Floris P de Lange; Joke S Kalkman; Gijs Bleijenberg; Peter Hagoort; Sieberen P van der Werf; Jos W M van der Meer; Ivan Toni Journal: Brain Date: 2004-07-07 Impact factor: 13.501
Authors: Daniel M Forton; Peter Karayiannis; Nadiya Mahmud; Simon D Taylor-Robinson; Howard C Thomas Journal: J Virol Date: 2004-05 Impact factor: 5.103
Authors: C Müller; S Pongratz; J Pidlich; E Penner; A Kaider; M Schemper; M Raderer; W Scheithauer; P Ferenci Journal: Eur J Gastroenterol Hepatol Date: 1998-10 Impact factor: 2.566
Authors: K Weissenborn; J C Ennen; M Bokemeyer; B Ahl; U Wurster; H Tillmann; C Trebst; H Hecker; G Berding Journal: Gut Date: 2006-05-08 Impact factor: 23.059
Authors: Diana V Stefanova-Petrova; Anelia H Tzvetanska; Elisaveta J Naumova; Anastasia P Mihailova; Evgenii A Hadjiev; Rumiana P Dikova; Mircho I Vukov; Konstantin G Tchernev Journal: World J Gastroenterol Date: 2007-12-28 Impact factor: 5.742